Caribbean Patient Recruitment Methodology: 2026 Pharma Guide

Caribbean patient recruitment for clinical and market research draws on the region's distinctive disease prevalence landscape. Diabetes affects approximately 12 percent of Caribbean adults, three to four times the prevalence rate in most Western markets. Hypertension affects 30 to 40 percent of adults across most Caribbean territories. Cardiovascular disease is the leading cause of death across the region. These epidemiological realities make Caribbean populations strategically important to pharmaceutical sponsors developing therapeutics for cardiometabolic conditions, oncology, and an expanding range of therapeutic areas. Effective patient recruitment combines HCP-mediated referral, pharmacy-based screening, patient association networks, database recall under appropriate consent, and country-specific ethics committee approvals for research involving protected health information.

Why Patient Recruitment in the Caribbean Is Different

Patient research in the Caribbean follows the same fundamental ethical principles as research conducted in larger markets, but operational execution and methodological design diverge in important ways. Five factors define Caribbean patient recruitment.

Disease prevalence is structurally elevated. Caribbean populations carry one of the world's highest diabetes prevalence rates, with adult prevalence estimated at 12 percent compared to approximately 11 percent globally. Hypertension prevalence at 30-40 percent of adults exceeds most Western markets. Sickle cell disease has high carrier rates across populations of African ancestry. These elevated rates create research opportunity because adequate sample sizes are achievable from smaller absolute populations, but also clinical context where Caribbean patient experience differs meaningfully from research populations in temperate markets.

The diaspora dimension changes patient journeys. Caribbean patients with serious conditions frequently travel to the United States, Canada, or the United Kingdom for advanced care. Treatment journeys do not begin and end within national borders. Research that ignores this dimension produces incomplete data on actual care utilization, treatment decisions, and outcomes. Effective programs include diaspora interviews where appropriate, conducted from US, Canadian, or UK collection points alongside in-market work.

Healthcare access varies dramatically by setting and income. Public hospital patients in the Caribbean experience different care pathways than private-system patients. A patient with type 2 diabetes treated through Jamaica's public clinic system may receive different medication, monitoring frequency, and education than a patient managed through private specialist care. Patient recruitment that draws exclusively from one care setting misses the variance pharmaceutical sponsors typically need to understand.

Cultural context affects treatment-seeking and disclosure. Patient willingness to discuss certain conditions varies by Caribbean culture and country. Mental health conditions still carry stigma in much of the region, affecting recruitment for depression, anxiety, and substance use research. Certain chronic conditions require sensitively-designed recruitment approaches.

Language and literacy considerations matter. Patient-facing instruments need to be developed in the appropriate language (English in Jamaica, Trinidad, Barbados, Bahamas; Spanish in Dominican Republic, Puerto Rico) and at reading levels accessible to the actual patient population.

The Caribbean Disease Burden Reality

These prevalence rates mean recruitment for diabetes patient research in Jamaica can practically target adult samples of 200-500 from screening of 2,000-4,000 individuals. Recruitment for rare disease research, by contrast, requires more focused channels and longer timelines.

Recruitment Channels for Caribbean Patient Research

No single channel reliably delivers Caribbean patients at the volumes most pharmaceutical research needs. Programs combine channels based on therapeutic area, urgency, and study design.

HCP-Mediated Referral

Cooperating physicians refer eligible patients to research participation after the patient's appointment or treatment visit. This channel works well for chronic disease research because the physician has confirmed clinical diagnosis and can identify patients meeting basic eligibility before the research firm makes contact. HCP-mediated recruitment requires established physician relationships, clear ethical separation between care and research, IRB-approved patient information sheets, and a practical workflow that does not burden the physician's clinical practice. Typical yield: 10-25 percent of physician-referred patients agree to participate when contacted, depending on study burden and compensation. See also: Caribbean HCP Research Methodology.

Pharmacy-Based Recruitment

Patients picking up prescriptions for relevant medications are approached at the pharmacy counter or via pharmacy-assisted contact. Particularly effective for diabetes, hypertension, and other high-prevalence chronic conditions where prescription pickup is regular and predictable. Pharmacy-based recruitment in the Caribbean works well with chain pharmacy networks (Fontana in Jamaica, Carlton in Trinidad, Walgreens in Puerto Rico) and selectively with independent pharmacies in concentrated retail areas.

Patient Association and Advocacy Networks

Caribbean diabetes associations, cancer support organizations, sickle cell foundations, and mental health advocacy groups maintain networks of affected patients who may participate in appropriately-designed research. Patient association partnerships work best when the research has perceived community benefit, not pure commercial sponsor focus. Association channels are particularly valuable for rare and complex disease research where general recruitment is impractical, and for longitudinal studies needing engaged participants.

Database Recall

Previous research participants who provided re-contact consent form a recruitment pool for new studies. Hope Research Group maintains a Caribbean patient research panel with appropriate re-contact consent for diabetes, hypertension, cardiovascular, oncology, and selected other conditions. Database recall is fastest and most cost-efficient when applicable but requires ongoing panel maintenance, re-consent for new studies, and verification that prior participants still meet current eligibility criteria.

Community Outreach

Community-based recruitment uses health fairs, parish-level community organizations, and faith-based networks where appropriate. Slower than other methods but particularly useful for reaching populations with limited healthcare access, and for research requiring representative cross-sections beyond patients already engaged with the medical system.

Digital and Social Media

Digital recruitment for Caribbean patient research is growing but requires care. Facebook is the dominant social platform across most Caribbean markets and supports geographic targeting. WhatsApp Business is increasingly used for patient communication. Digital channels work for higher-prevalence conditions but produce variable sample quality. Programs typically combine digital outreach with HCP-mediated or pharmacy-based screening for verification of stated condition.

Therapeutic Area Considerations

Patient recruitment approach varies meaningfully by therapeutic area.

Diabetes is the most-commissioned Caribbean therapeutic area patient research. High prevalence supports large samples. Recruitment combines HCP-mediated referral, pharmacy-based screening at insulin and oral hypoglycemic pickup, and Caribbean diabetes association partnerships. Common study designs include treatment satisfaction studies, adherence research, GLP-1 receptor agonist user experience, and continuous glucose monitoring adoption research.

Hypertension is similar to diabetes in recruitment approach. High prevalence, broad pharmacy footprint for antihypertensive medications, manageable diagnostic certainty. Often combined with diabetes research for comorbid cardiometabolic studies.

Oncology involves smaller patient populations per country that constrain absolute sample sizes. Recruitment heavily depends on academic medical center partnerships (UWI hospitals, EWMSC, CEDIMAT, Centro Médico Puerto Rico) where oncology patients concentrate. Studies typically sample 25-50 patients per country for major tumor types. Patient experience research, treatment satisfaction studies, and quality of life measurement are common designs.

Mental Health is a growing therapeutic area research category, often outpacing recruitment infrastructure. Stigma considerations require sensitive design and discreet recruitment channels. Telehealth-based recruitment can support discretion. Compensation should fairly value participant time and emotional labor.

Rare and Specialty Diseases: Sickle cell disease research can leverage Caribbean prevalence patterns. Rare disease research generally requires international collaboration with specialty centers and may not be feasible as Caribbean-only studies for very rare conditions.

Pediatric and Family Research requires parent or guardian consent and additional ethics review. Family research (asthma, allergy, family caregiver studies for chronic disease) requires recruitment that engages multiple household members.

Ethics and IRB Considerations

Patient research involving protected health information, clinical data, or any patient-level component typically requires formal ethics committee approval. Ethics approval timelines typically run 60-90 days for full reviews.

• Jamaica: Ministry of Health Research Ethics Committee reviews patient research with health system implications. Academic-affiliated research may also require UWI institutional review.
• Trinidad and Tobago: UWI institutional review boards conduct ethics review for academically-affiliated research. Hospital ethics committees review research conducted at major institutions.
• Dominican Republic: CONABIOS (Consejo Nacional de Bioética en Salud) provides national-level bioethics review. Hospital-level ethics committees may also apply.
• Puerto Rico: US Department of Health and Human Services and FDA frameworks apply, with university-based IRBs providing review. Functionally identical to mainland US research.
• Barbados: UWI Cave Hill institutional review board and Ministry of Health ethics review.
• OECS and smaller markets: Country-specific Ministry of Health ethics review where available; regional UWI Open Campus support in some cases.

Studies that involve only patient perception and behavior without protected health information access may qualify for exempt status, depending on country and reviewing body.

Compensation Standards for Caribbean Patient Participation

Patient compensation in Caribbean research follows the principle of fair value for time and inconvenience without becoming coercive inducement to participate. Compensation should be appropriate to local economic context.

Longitudinal Study Retention

Multi-visit and multi-month patient research requires retention strategies specific to Caribbean operational context. Retention rates of 70-85 percent are achievable for well-designed 6-month longitudinal studies in the Caribbean. Lower retention often signals design issues rather than population unwillingness.

• Regular communication through preferred patient channels (phone, WhatsApp, email depending on age cohort and preference) maintains engagement between visits.
• Incremental compensation paid at each visit or milestone rather than at study end supports continued participation.
• Travel and time reimbursement for in-person visits prevents attrition from logistical burden.
• Flexible scheduling that accommodates patient work and family commitments avoids unnecessary drop-out.
• Country-specific holidays and seasonal considerations built into study calendar avoid recruitment dead zones (Christmas-New Year period, Carnival weeks in Trinidad, Easter periods, etc.).

The Diaspora Component

Pharmaceutical research that ignores Caribbean diaspora misses important care delivery dimensions. Caribbean patients with complex conditions frequently travel to US (Miami, New York, Boston, Houston) or Canada (Toronto) for specialist consultation or treatment, maintain healthcare relationships in both home country and diaspora destination, and receive prescriptions filled in different countries.

Effective Caribbean patient journey research often includes diaspora interviews conducted from US or Canadian collection points to capture the full care experience. This is particularly important for oncology, complex cardiovascular care, and other specialty areas where regional capacity is limited.

Common Pitfalls in Caribbean Patient Recruitment

• Importing US or European sample size targets without adjustment. Programs needing n=400 oncology patients per Caribbean country are usually not feasible.
• Single-channel recruitment dependency. Programs relying exclusively on HCP referral or exclusively on pharmacy screening miss patients that other channels would reach.
• Ignoring practice setting variance. Pooling public hospital, private practice, and academic medical center patients without stratification loses important treatment-decision variance.
• Underestimating ethics approval timelines. Programs that assume 30-day ethics review consistently underestimate; 60-90 days is more realistic.
• Designing instruments at university reading levels. Patient instruments need to be accessible to actual patient populations, including those with limited formal education.
• Single-language regional studies. Programs covering both English-speaking and Spanish-speaking Caribbean need bilingual capability with cultural adaptation, not just translation.
• Skipping diaspora consideration. Programs studying complex Caribbean patient journeys without diaspora interviews produce incomplete pictures of actual care utilization.

Costs by Methodology

How to Choose a Patient Recruitment Vendor in the Caribbean

The vendor selection markers that reliably distinguish capable firms from generalist research companies. Ask for:

• Years of patient research experience in the Caribbean with documented therapeutic area work
• Ethics committee submission history with specific country IRBs the firm has worked with
• Patient panel size and consent maintenance practices
• HCP and pharmacy network partnerships that support recruitment
• Two or three pharmaceutical sponsor references willing to discuss program execution
• Sample reports from comparable patient research programs (appropriately de-identified)
• Bilingual operational capability for pan-Caribbean studies
• Specific recruitment specialists who would work on your program

Vendors that respond with general capability statements rather than specific examples should be approached with caution. Patient research is operationally demanding and ethical considerations require operational maturity that takes years to develop.

Frequently Asked Questions

Related Hope Research Group Resources

• Healthcare and Pharmaceutical Market Research
• Caribbean Pharma Fieldwork: 2026 Complete Guide
• Caribbean HCP Research Methodology
• Jamaica Market Research Overview
• Dominican Republic Market Research
• How to Conduct Market Research in Jamaica